KAPA Kairos Pharma, Ltd.
-
Kairos Pharma, Beat Consensus Estimates
Wednesday, August 12, 2026 · 12:00 AM ET
Kairos Pharma, (KAPA) reported a loss of $0.06 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.09 per share. The company beat consensus estimates by 33.33%.
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company. It focused on developing a diversified pipeline of cutting-edge oncology therapeutics born from structural biology to reverse cancer drug resistance and the inhibitory effects of cancer on the immune system. Kairos Pharma Ltd. is based in Los Angeles, California.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.06)
Earnings Whisper®
—
Consensus Estimate
($0.09)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—